Last reviewed · How we verify

atomoxetine (or placebo)

University of Arizona · FDA-approved active Small molecule

atomoxetine (or placebo) is a Norepinephrine reuptake inhibitor (NRI) Small molecule drug developed by University of Arizona. It is currently FDA-approved for Attention-deficit/hyperactivity disorder (ADHD) in children and adults, ADHD in adolescents.

Atomoxetine selectively inhibits the reuptake of norepinephrine in the brain, increasing norepinephrine levels in synapses.

Atomoxetine selectively inhibits the reuptake of norepinephrine in the brain, increasing norepinephrine levels in synapses. Used for Attention-deficit/hyperactivity disorder (ADHD) in children and adults, ADHD in adolescents.

At a glance

Generic nameatomoxetine (or placebo)
SponsorUniversity of Arizona
Drug classNorepinephrine reuptake inhibitor (NRI)
TargetNorepinephrine transporter (NET)
ModalitySmall molecule
Therapeutic areaPsychiatry / Neurology
PhaseFDA-approved

Mechanism of action

Atomoxetine is a selective norepinephrine reuptake inhibitor (NRI) that blocks the norepinephrine transporter, preventing the reabsorption of norepinephrine from the synaptic cleft. This increases norepinephrine availability in the prefrontal cortex and other brain regions involved in attention and executive function. Unlike stimulant medications, it does not directly release norepinephrine or dopamine and has minimal abuse potential.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about atomoxetine (or placebo)

What is atomoxetine (or placebo)?

atomoxetine (or placebo) is a Norepinephrine reuptake inhibitor (NRI) drug developed by University of Arizona, indicated for Attention-deficit/hyperactivity disorder (ADHD) in children and adults, ADHD in adolescents.

How does atomoxetine (or placebo) work?

Atomoxetine selectively inhibits the reuptake of norepinephrine in the brain, increasing norepinephrine levels in synapses.

What is atomoxetine (or placebo) used for?

atomoxetine (or placebo) is indicated for Attention-deficit/hyperactivity disorder (ADHD) in children and adults, ADHD in adolescents.

Who makes atomoxetine (or placebo)?

atomoxetine (or placebo) is developed and marketed by University of Arizona (see full University of Arizona pipeline at /company/university-of-arizona).

What drug class is atomoxetine (or placebo) in?

atomoxetine (or placebo) belongs to the Norepinephrine reuptake inhibitor (NRI) class. See all Norepinephrine reuptake inhibitor (NRI) drugs at /class/norepinephrine-reuptake-inhibitor-nri.

What development phase is atomoxetine (or placebo) in?

atomoxetine (or placebo) is FDA-approved (marketed).

What are the side effects of atomoxetine (or placebo)?

Common side effects of atomoxetine (or placebo) include Nausea, Decreased appetite, Insomnia, Dizziness, Fatigue, Headache.

What does atomoxetine (or placebo) target?

atomoxetine (or placebo) targets Norepinephrine transporter (NET) and is a Norepinephrine reuptake inhibitor (NRI).

Related